Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Venetoclax in Combination With ASTX727, an All-ORal Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN With Excess Blasts (VICTORY-MDS/MPN): a Randomized, Phase 2 Trial

Next Previous
Trial Profile

Venetoclax in Combination With ASTX727, an All-ORal Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN With Excess Blasts (VICTORY-MDS/MPN): a Randomized, Phase 2 Trial

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cedazuridine/decitabine (Primary) ; Venetoclax (Primary)
  • Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders
  • Focus Therapeutic Use
  • Acronyms VICTORY-MDS/MPN

Most Recent Events

  • 12 Dec 2023 Trial design presented at the 65th American Society of Hematology Annual Meeting and Exposition
  • 17 Jun 2023 Planned number of patients changed from 120 to 132.
  • 25 Apr 2023 Planned End Date changed from 31 Aug 2024 to 31 Aug 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top